REGIMMUNE-LIMITED
7.11.2022 08:55:38 CET | Business Wire | Press release
REGiMMUNE Limited, a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for immune disorders and cancer, today announced that the Phase 2b clinical data from 49 patients receiving RGI-2001 for the prevention of acute graft-versus-host disease (aGVHD) will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana on December 12, 2022.
This is an open label, single-arm Phase 2 study, evaluating the safety and efficacy of RGI-2001 for the prevention of aGVHD in subjects following allogeneic hematopoietic stem cell transplantation (HSCT). This study tests the hypothesis that RGI-2001 prevents GVHD by expanding regulatory T cells soon after allogeneic HSCT. The incidence and severity of aGVHD was evaluated in patients treated with RGI-2001 in addition to standard GVHD prevention medications. “Based on the analysis, RGI-2001 showed reduced incidence of aGVHD with an excellent safety profile. I am thrilled that the RGI-2001 study results have been selected for oral presentation at the ASH meeting. We look forward to sharing future findings as we work to deliver breakthrough immune medicines by harnessing the power of regulatory T cells,” said Kenzo Kosuda, CEO at REGiMMUNE Limited.
Session Name: Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Novel Therapies for Graft-versus-Host Disease
Session Date and Time: Monday, December 12, 2022, 10:30 - 12:00 p.m. CT
Presentation time: 11:45 a.m. CT
Location: Ernest N. Morial Convention Center, 252-254 and online
Presenter: Yi-Bin Chen, MD
Publication Number: 774
Title: RGI-2001 Infusion for Prevention of Acute GVHD after Allogeneic Hematopoietic Cell Transplantation
Submission ID: 162512
About RGI-2001
RGI-2001 is a liposomal formulation of an alpha-galactosylceramide (alpha-GalCer) analog. Alpha-GalCer is a ligand for CD1d expressed on antigen presenting cells and invariant natural killer T cells (iNKT). Liposomal alpha-GalCer promotes tolerogenic immune cascades, resulting in the activation and expansion of regulatory T cells (Tregs). RGI-2001 is REGiMMUNE’s lead drug candidate currently in Phase 3 planning for the prophylaxis of acute graft-versus-host disease (aGVHD).
About REGiMMUNE Limited
REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies by harnessing the power of regulatory T cells (Tregs). REGiMMUNE is creating a pipeline of novel product candidates that either enhance Treg activities for immune diseases or suppress Treg activities for cancer.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221106005119/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Red Sea Global Unveils Nammos Resort AMAALA, Introducing Nammos’ First Resort Hotel Globally8.9.2026 10:59:00 CEST | Press release
The internationally renowned lifestyle and hospitality brand makes its debut in the Middle East Red Sea Global (RSG), the regenerative tourism developer, today announced the opening of Nammos Resort AMAALA, marking the launch of Nammos’ first resort hotel globally and a significant addition to AMAALA’s growing lifestyle and hospitality offering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908621917/en/ A marvellous view of the night sky from inside the resort hotel Set along the shores of Triple Bay with sweeping views across the Red Sea and Dumega Bay and designed around Nammos’ philosophy of Endless Joy, Nammos Resort AMAALA introduces the brand’s distinctive blend of Mediterranean sophistication and vibrant social energy to one of the world’s most comprehensive wellness destinations. “Nammos Resort AMAALA strengthens the diversity of experiences available across the destination bringing the unmistakable energy and s
Icon Solutions and MongoDB Benchmark Shows IPF Processing 6,000 Payments per Second with Zero Data Loss Under Failure8.9.2026 10:54:00 CEST | Press release
Joint benchmark on MongoDB Atlas demonstrates near-linear scalability, sub-second end-to-end latency and recovery from application and database node failures without losing a single transaction. Icon Solutions and MongoDB today published the results of a joint benchmark showing that the Icon Payments Framework (IPF), running on MongoDB Atlas, processed 6,000 end-to-end payment transactions per second (around 430,000 database operations per second) with a mean end-to-end latency of 0.51 seconds, and recovered from both application and database node failures with zero data loss. Account-to-account payment volumes are moving rapidly onto instant rails. Traffic is migrating from net-settlement schemes to instant schemes, and direct debit volumes are expected to partially move to request-to-pay with settlement through instant schemes. For banks, that means sharper traffic peaks, a growing share of payments bound to scheme SLAs of a few seconds, and no tolerance for downtime. Sustaining seve
NTT DATA Deploys AI-Powered Platform to Elevate Global Infrastructure Operations8.9.2026 10:00:00 CEST | Press release
Real‑time monitoring and predictive analytics improve stability and efficiency. Scope includes AI-enabled operations for IT and cloud infrastructure, SAP Basis and network operations worldwide. NTT DATA, a global leader in AI, digital business and technology services, is expanding the deployment of its AI-powered infrastructure operations platform to support complex global enterprise environments. The platform combines real time monitoring, predictive analytics and intelligent automation to enhance operational resilience, efficiency and visibility. Deployment of these capabilities includes support for one of the largest commercial vehicle manufacturers. “Our AI-powered platform significantly increases transparency and automation, providing the foundation for greater stability, faster response times and a future-ready IT architecture,” said Abhijit Dubey, CEO and Chief AI Officer, NTT DATA, Inc. “Our work with Daimler Truck is one example of how we canoperate global IT infrastructures s
Wolters Kluwer launches Libra Academy across Europe to help legal professionals realize the full value of legal AI8.9.2026 09:01:00 CEST | Press release
Developed by lawyers for lawyers, Libra Academy brings together learning resources, use cases and a European user community to accelerate AI adoption and customer success Wolters KluwerLegal & Regulatory today announced the launch of Libra Academy, a new learning and enablement platform around the company’s legal AI workspace Libra by Wolters Kluwer, designed to help legal professionals confidently integrate AI into their daily work. As legal teams increasingly look to move beyond experimentation and achieve measurable productivity gains, they face a new challenge: keeping pace with an AI landscape that evolves faster than traditional training can follow. New features, models, and use cases emerge continuously, making it difficult for busy legal professionals to stay current while managing the demands of their daily work. Libra Academy was created to close this gap. Built directly into the Libra experience, it provides continuous learning that evolves alongside the platform, helping cu
James von Moltke Joins Warburg Pincus8.9.2026 09:00:00 CEST | Press release
Former President and Chief Financial Officer, Deutsche Bank AG, Joins Warburg Pincus in Europe as a senior advisor and Executive-in-Residence Warburg Pincus, the pioneer of private equity global growth investing, today announced the appointment of James von Moltke as a senior advisor and Executive-in-Residence. Mr. von Moltke, who takes up the role with immediate effect, will bring his extensive industry expertise to support the firm’s European activities with particular focus on the financial and technology sectors, where he will support the identification and evaluation of new potential investment opportunities. He will also play an active role in value creation across the firm’s existing portfolio in Europe. Mr. von Moltke brings significant industry experience to the firm, having served as President of Deutsche Bank AG since 2022 and as Chief Financial Officer and Member of the Management Board of the Group for nine years. During this time, he played a key role in driving the bank’
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom